Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3
A cheap blood pressure drug may soften the dense scar tissue around pancreatic tumours so chemotherapy and immune cells can get in. Early trials look encouraging.
Losartan inhibits angiotensin II and TGF-beta-driven fibrosis and, in mouse models, decompresses tumour vessels and improves drug delivery. A single-arm phase 2 (Massachusetts General Hospital) adding losartan to FOLFIRINOX and chemoradiation in locally advanced pancreatic cancer reported a high R0 resection rate, and a randomised phase 2 with added immunotherapy has followed. Losartan is off patent and costs a few dollars a month. The proposal is a publicly funded randomised phase 3 of losartan plus standard neoadjuvant therapy versus standard therapy alone in borderline resectable and locally advanced pancreatic cancer.
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
- Cold tumours and the immunosuppressive microenvironment · Most tumours keep the immune system out or asleep, so immunotherapy helps only a minority.
Pages like this
not linked directly; found by shared links- IdeaBlock the complement signal that recruits tumour-protecting cells
Shares No incentive to repurpose cheap drugs, Cold tumours and the immunosuppressive microenvironment, Pancreatic ductal adenocarcinoma.
- IdeaCheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
Shares Epithelial–mesenchymal transition & drug efflux, No incentive to repurpose cheap drugs.
- PersonTheodore S. Hong
Shares Massachusetts General Hospital Cancer Center, Pancreatic ductal adenocarcinoma.
- InstitutionSalk Institute Cancer Center
Shares Cold tumours and the immunosuppressive microenvironment, Pancreatic ductal adenocarcinoma.
- IdeaImplant a tiny device that tests twenty drugs inside the patient's own tumour
Shares Massachusetts General Hospital Cancer Center, Cold tumours and the immunosuppressive microenvironment.
- PathwayHippo–YAP/TAZ
Shares Massachusetts General Hospital Cancer Center, Epithelial–mesenchymal transition & drug efflux.
- IdeaConfirm low-dose olanzapine for appetite and weight in advanced cancer worldwide
Shares No incentive to repurpose cheap drugs, Pancreatic ductal adenocarcinoma.
- IdeaTrain the bone marrow to make better anti-tumour immune cells
Shares No incentive to repurpose cheap drugs, Cold tumours and the immunosuppressive microenvironment.